147 related articles for article (PubMed ID: 10699717)
1. Desolvation process and surface characteristics of HSA-nanoparticles.
Weber C; Kreuter J; Langer K
Int J Pharm; 2000 Mar; 196(2):197-200. PubMed ID: 10699717
[TBL] [Abstract][Full Text] [Related]
2. Desolvation process and surface characterisation of protein nanoparticles.
Weber C; Coester C; Kreuter J; Langer K
Int J Pharm; 2000 Jan; 194(1):91-102. PubMed ID: 10601688
[TBL] [Abstract][Full Text] [Related]
3. A simple improved desolvation method for the rapid preparation of albumin nanoparticles.
Jahanban-Esfahlan A; Dastmalchi S; Davaran S
Int J Biol Macromol; 2016 Oct; 91():703-9. PubMed ID: 27177461
[TBL] [Abstract][Full Text] [Related]
4. Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation.
Langer K; Anhorn MG; Steinhauser I; Dreis S; Celebi D; Schrickel N; Faust S; Vogel V
Int J Pharm; 2008 Jan; 347(1-2):109-17. PubMed ID: 17681686
[TBL] [Abstract][Full Text] [Related]
5. Optimization of the preparation process for human serum albumin (HSA) nanoparticles.
Langer K; Balthasar S; Vogel V; Dinauer N; von Briesen H; Schubert D
Int J Pharm; 2003 May; 257(1-2):169-80. PubMed ID: 12711172
[TBL] [Abstract][Full Text] [Related]
6. Albumin nanoparticles with predictable size by desolvation procedure.
Storp Bv; Engel A; Boeker A; Ploeger M; Langer K
J Microencapsul; 2012; 29(2):138-46. PubMed ID: 22329480
[TBL] [Abstract][Full Text] [Related]
7. Preparation and in vitro characterization of HSA-mPEG nanoparticles.
Lin W; Garnett MC; Schacht E; Davis SS; Illum L
Int J Pharm; 1999 Nov; 189(2):161-70. PubMed ID: 10536244
[TBL] [Abstract][Full Text] [Related]
8. A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation.
Wacker M; Zensi A; Kufleitner J; Ruff A; Schütz J; Stockburger T; Marstaller T; Vogel V
Int J Pharm; 2011 Jul; 414(1-2):225-32. PubMed ID: 21571055
[TBL] [Abstract][Full Text] [Related]
9. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells.
Ulbrich K; Michaelis M; Rothweiler F; Knobloch T; Sithisarn P; Cinatl J; Kreuter J
Int J Pharm; 2011 Mar; 406(1-2):128-34. PubMed ID: 21185364
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of obidoxime into human serum albumin nanoparticles: optimisation of preparation parameters for the development of a stable formulation.
Kufleitner J; Worek F; Kreuter J
J Microencapsul; 2010; 27(7):594-601. PubMed ID: 20923399
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles.
Avachat AM; Oswal YM; Gujar KN; Shah RD
Curr Drug Deliv; 2014; 11(3):359-70. PubMed ID: 24893995
[TBL] [Abstract][Full Text] [Related]
12. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.
Dreis S; Rothweiler F; Michaelis M; Cinatl J; Kreuter J; Langer K
Int J Pharm; 2007 Aug; 341(1-2):207-14. PubMed ID: 17478065
[TBL] [Abstract][Full Text] [Related]
13. Preparation of Bovine Serum Albumin (BSA) nanoparticles by desolvation using a membrane contactor: a new tool for large scale production.
Yedomon B; Fessi H; Charcosset C
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):398-405. PubMed ID: 23811438
[TBL] [Abstract][Full Text] [Related]
14. Asymmetrical flow field-flow fractionation for human serum albumin based nanoparticle characterisation and a deeper insight into particle formation processes.
John C; Langer K
J Chromatogr A; 2014 Jun; 1346():97-106. PubMed ID: 24800970
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle size and production efficiency are affected by the presence of fatty acids during albumin nanoparticle fabrication.
Luebbert CC; Clarke TM; Pointet R; Frahm GE; Tam S; Lorbetskie B; Sauvé S; Johnston MJW
PLoS One; 2017; 12(12):e0189814. PubMed ID: 29281685
[TBL] [Abstract][Full Text] [Related]
16. Preparation of sterically stabilized human serum albumin nanospheres using a novel Dextranox-MPEG crosslinking agent.
Lin W; Coombes AG; Garnett MC; Davies MC; Schacht E; Davis SS; Illum L
Pharm Res; 1994 Nov; 11(11):1588-92. PubMed ID: 7532861
[TBL] [Abstract][Full Text] [Related]
17. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.
Wartlick H; Spänkuch-Schmitt B; Strebhardt K; Kreuter J; Langer K
J Control Release; 2004 May; 96(3):483-95. PubMed ID: 15120904
[TBL] [Abstract][Full Text] [Related]
18. Preparation and in Vitro Analysis of Human Serum Albumin Nanoparticles Loaded with Anthracycline Derivatives.
Kimura K; Yamasaki K; Nakamura H; Haratake M; Taguchi K; Otagiri M
Chem Pharm Bull (Tokyo); 2018; 66(4):382-390. PubMed ID: 29607904
[TBL] [Abstract][Full Text] [Related]
19. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina.
Kim H; Robinson SB; Csaky KG
Pharm Res; 2009 Feb; 26(2):329-37. PubMed ID: 18958405
[TBL] [Abstract][Full Text] [Related]
20. Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties.
Wacker M; Chen K; Preuss A; Possemeyer K; Roeder B; Langer K
Int J Pharm; 2010 Jun; 393(1-2):253-62. PubMed ID: 20417701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
